Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YLHMX
ADC Name
Rituximab-Compound (la) DAR 4
Synonyms
Rituximab Compound (la)
   Click to Show/Hide
Organization
Orum Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Non Hodgkin lymphoma [ICD11:2B33]
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Rituximab
  Antibody Info 
Antigen Name
B-lymphocyte antigen CD20 (MS4A1)
  Antigen Info 
Payload Name
NeoDegrader P1
  Payload Info 
Therapeutic Target
Protein cereblon (CRBN)
  Target Info 
Linker Name
Rituximab-Compound (la) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.8
nM
Daudi cells
Burkitt lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.80 nM Positive CD20 expression (CD20+++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Burkitt lymphoma Daudi cells CVCL_0008
References
Ref 1 Neodegrader conjugates; 2021-10-07.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.